sponsored
PatientsVille.com Logo

PatientsVille

Glivec Medical Research Studies

Up-to-date List of Glivec Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Glivec Medical Research Studies

Rank Status Study
1 Recruiting Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: GIST and CML
Intervention: Drug: STI571
Outcome Measures: Number of patients receiving imatinib;   Frequency and nature of serious adverse events
2 Recruiting Randomized ph Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: nilotinib;   Drug: imatinib
Outcome Measures: to determine the comparative efficacy between imatinib dose escalation and nilotinib, in terms of CCyR) after 6 months of treatment, for patients with CML in chronic phase with suboptimal response to imatinib standard dose;   to compare the rate of major molecular response (MMR) between 2 arms at 12 months;   to evaluate safety and tolerability of imatinib 600mg/daily and nilotinib 400mg twice a day;   to evaluate the rate of CCyR at 12, 18 and 24 months on study;   time to CCyR;   duration of CCyR;   Progression-Free Survival;   Event-Free Survival (EFS);   Overall survival (OS)
3 Recruiting A Study of Nilotinib Versus Imatinib in GIST Patients
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107);   Drug: imatinib (STI571)
Outcome Measures: To compare Progression Free Survival (PFS) of nilotinib and imatinib when used as initial therapy in patents with unresectable and/ or metastatic GIST.;   To compare disease control rate (DCR) of nilotinib and imatinib;   To compare time to treatment failure (TTF) of nilotinib and imatinib;   To compare overall survival (OS) of nilotinib and imatinib;   To compare time to progression (TTP), response rate (RR), time to tumor response and assess duration of response of nilotinib and imatinib;   To compare safety and tolerability of nilotinib and imatinib
4 Recruiting A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients
Condition: 3rd Line GIST
Intervention: Drug: STI571 + BKM120
Outcome Measures: Frequency and characteristics of dose limiting toxicities (DLTs) at each dose level during the first cycle of therapy;   Frequency and characteristics of DLTs at each dose level during the first cycle of therapy. Type, frequency and severity of adverse drug reactions.;   Imatinib and BKM120 plasma concentrations vs time profile, and basic PK parameters, including but not limited to AUC, Cmax, Tmax, CL/F.;   Clinical benefit rate (CBR) defined as the rate of confirmed complete response (CR) or partial response (PR), or stable disease (SD) which lasts for at least 16 weeks.
5 Recruiting Ipilimumab and Imatinib Mesylate in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Ipilimumab;   Drug: Imatinib Mesylate
Outcome Measure: Maximum Tolerated Dose (MTD) of Ipilimumab and Imatinib Mesylate
6 Recruiting Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
Condition: Chronic Myeloid Leukemia
Interventions: Drug: mesylate imatinib capsule;   Drug: Glivec
Outcome Measure: Area Under Curve (AUC) Time Frame: predose, 0.5,1,1.5,2,3,5,8,12,24,48,72hours post-dose
7 Recruiting Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib, Imatinib
Outcome Measure: the cumulative rate of MMR
8 Recruiting Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus
Conditions: Diabetes Mellitus, Type I;   Diabetes Mellitus, Insulin-Dependent, 1;   Type 1 Diabetes Mellitus;   Insulin-Dependent Diabetes Mellitus 1;   IDDM
Interventions: Drug: Imatinib Mesylate;   Drug: Placebo (For imatinib mesylate)
Outcome Measures: Effect of treatment with imatinib versus placebo in individuals;   Mean area under the stimulated C-peptide curve (AUC) curve at 12 months;   Mean area under the stimulated C-peptide curve (AUC) over 4 hours at 24 months;   Change in HbA1c levels over time;   Change in Insulin dose (units/kg) over time;   Number of severe hypoglycemic events;   Number and severity of adverse events
9 Recruiting Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib
Outcome Measures: To test the ability of imatinib to maintain the cytogenetic response in patients who achieved complete cytogenetic response (CCyR) at 12 months with first line nilotinib.;   To assess the effects of nilotinib followed by imatinib on molecular response;   To assess the effects of nilotinib followed by imatinib on BCR-ABL mutations
10 Recruiting Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia
Condition: Myeloid Leukemia, Chronic, Chronic Phase
Interventions: Drug: Imatinib;   Drug: Dasatinib
Outcome Measure: 5-year event free survival
11 Recruiting A Global Imatinib and Nilotinib Pregnancy Exposure Registry
Condition: All Indications for Glivec/Gleevec and Tasigna
Interventions: Drug: Tasigna;   Drug: Gleevec
Outcome Measures: Monitor pregnancies exposed to Imatinib or Nilotinib to estimate prevalence of birth defects;   Assess impact on maternal CML disease when treatment is interrupted;   Assess post 12 month post-delivery data on maternal and infant status
12 Recruiting Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: Imatinib;   Drug: Dasatinib
Outcome Measures: Proportion of subjects who achieve Major Molecular Response (MMR) rate;   Molecular Response over time - Proportion of randomized subjects who achieve MMR, MR4 and MR4.5 at each time-point from Day 1 treatment with first line Imatinib;   Cytogenetic Response over time - proportion of randomized subjects who achieve Complete Cytogenetic Response (CCyR) or major cytogenetic response (MCyR) at each time-point from Day 1 treatment with first line Imatinib;   Progression Free Survival (PFS) - PFS is defined as the time from randomization date to progression date or death date, whichever occurs first. Subjects who neither progress nor die, will be censored;   Overall Survival (OS)- OS is defined as the time from randomization date to death date. Subjects who have not died, will be censored on the last date they are known to be alive;   Time to and duration of Response - Time to MMR is the time between randomization date and first date that MMR criteria are satisfied;   Time to and duration of Response - Time to MR4.5 is the time between randomization date and first date that MR4.5 criteria are satisfied;   Time to and duration of Response - Time to MR4 is the time between randomization date and first date that MR4 criteria are satisfied;   Time to and duration of Response - Time to CCyR is the time between randomization date and first date that CCyR criteria are satisfied;   Time to and duration of Response - Time to MCyR is the time between randomization date and first date that MCyR criteria are satisfied
13 Unknown  Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib
Outcome Measures: To determine the efficacy regarding major cytogenetic response within 12 months after randomization;   To determine the major cytogenetic response after 3 months versus 6-12 months after randomization;   To determine the efficacy of the molecular response within 12 and 24 months after randomization;   To determine the time to molecular progression within 24 months;   To determine the dynamics of the molecular response within 3 and 6 months after randomization expressed as the slope decreases in BCR-ABL-transcripts;   To determine tolerability
14 Recruiting Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)
Condition: Asthma
Interventions: Drug: Imatinib mesylate;   Drug: Placebo
Outcome Measures: Methacholine responsiveness;   Change in airway mast cell populations and phenotype.
15 Recruiting Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: imatinib mesylate;   Procedure: conventional surgery
Outcome Measures: Rate of disease recurrence at 2 years;   Rates of objective response (complete, partial, and stable);   Determine the safety and tolerability of this drug in these patients.
16 Unknown  Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck
Conditions: Cancer of the Head and Neck;   Carcinoma, Adenoid Cystic
Intervention: Drug: Imatinib
Outcome Measures: To assess progression-free survival under treatment with imatinib mesylate in patients with relapsing/metastatic adenoid cystic carcinoma of the head and neck overexpressing KIT.;   The secondary objectives are to estimate the objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST] criteria), disease control and overall survival.
17 Recruiting Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
Conditions: Graft Versus Host Disease;   Systemic Scleroderma
Interventions: Drug: imatinib mesylate;   Biological: rituximab;   Other: laboratory biomarker analysis;   Other: questionnaire administration
Outcome Measures: Significant clinical response;   Proportion of patients achieving a greater than or equal to 50% reduction in the daily corticosteroid dose;   Cumulative incidence of treatment failure;   Number of patients achieving improvement in cutaneous sclerosis;   Correlation of blood and skin biomarker profile with each therapeutic agent and clinical response;   Proportion of subjects with any percentage decline in any grade of sclerosis without increase in percentage of higher grades of sclerosis in other areas on the Vienna skin scale
18 Not yet recruiting A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Condition: Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
Interventions: Drug: Bosutinib;   Drug: Imatinib
Outcome Measures: Compare proportion of participants with Major Molecular Response (MMR) at 12 Months in the bosutinib arm with that of the imatinib arm;   Compare proportion of participants with MMR at 18 Months in the bosutinib treatment group with the imatinib treatment group;   To determine the duration of MMR in the bosutinib treatment group with the imatinib treatment group;   To determine the proportion of participants with Complete Cytogenetic Response (CCyR) by 12 Months in both treatment groups;   To determine the duration of CCyR in both treatment groups
19 Not yet recruiting Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: BL-8040
Outcome Measures: To assess the safety and tolerability of BL-8040 in combination with Imatinib in CML patients;   To assess the clinical efficacy of BL-8040 in combination with Imatinib
20 Unknown  Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
Condition: AML
Interventions: Drug: Glivec;   Drug: Mitoxantrone;   Drug: Topotecan;   Drug: AraC
Outcome Measure: To show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.

These studies may lead to new treatments and are adding insight into Glivec etiology and treatment.

A major focus of Glivec research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Glivec